RecruitingOBSERVATIONAL

Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC

This study focuses on people with advanced non-small cell lung cancer who received a powerful immunotherapy drug called pembrolizumab. This drug helps your body's immune system fight cancer, and while it works well for some, it doesn't for everyone. We're also trying to understand why some people experience side effects from the treatment. The main goal is to look closely at tumour samples from past patients to find clues, called 'biomarkers'. These biomarkers could help doctors predict who will respond best to pembrolizumab and who might experience more side effects. Ultimately, this research aims to improve how we treat lung cancer in the future and help doctors choose the best treatment for each person.

At a glance

Status

Recruiting

Sponsor

University Hospital, Brest

Enrolment target

Start

16 Apr 2021

Estimated completion

16 May 2025

Advanced Non Small Cell Lung Cancer

What is this study about?

This study is looking back at information from people who have already been treated for a type of advanced lung cancer called non-small cell lung cancer (NSCLC). These patients received a modern cancer treatment called immunotherapy, specifically a drug called pembrolizumab. This type of treatment helps your body's own immune system find and fight cancer cells.

While these immunotherapy drugs have been a big step forward in treating cancer, they don't work for everyone, and some people experience side effects. The researchers want to understand why some people respond well to the treatment and others don't, and why some develop side effects while others don't. By finding these answers, doctors hope to be better at predicting who will benefit most from treatment and who might need a different approach.

To do this, the scientists will be carefully examining tumour samples that were collected from these patients in the past. They will use a special advanced technology to look at the cells within the tumour in great detail. This will allow them to find specific patterns or 'signatures' that could explain why some people had a good response and others experienced side effects. The aim is to find new ways to predict how well a treatment will work for someone, leading to more personalised and effective cancer care in the future. The study is called 'PREDICTION' because it aims to predict these outcomes.

Key takeaways

Researches look at past patient data and tissue samples.
Aims to understand why immunotherapy works for some lung cancer patients but not others.
Hopes to predict who will respond well and who might have side effects.
Uses advanced technology to examine tumour samples closely.
Could help doctors choose better treatments for future patients.

Who may be eligible?

This study is looking back at information from adults who were treated for advanced non-small cell lung cancer in the past.

To be included, patients must have had a specific level of a protein called PD-L1 (50% or more) in their cancer cells. They also need to have received their first dose of the immunotherapy drug pembrolizumab between January 2017 and December 2019.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you an adult?
Were you diagnosed with advanced non-small cell lung cancer?
Did your cancer cells show PD-L1 levels of 50% or more?
Did you receive your first dose of pembrolizumab between January 2017 and December 2019?

Answer every question to see your result.

What does participation involve?

This is a 'retrospective' study, meaning it looks at information from patients who have already completed their treatment. If you fit the eligibility criteria, you won't need to do anything new. You won't have any appointments, assessments, or receive any new medication. Your participation would involve researchers using existing, anonymised medical records and tissue samples that were collected as part of your past care. There is no direct involvement for you as a patient in the present day.

Potential risks and benefits

Since this study involves looking at existing records and samples, there are no direct physical risks to you. Your personal information will be protected and anonymised. The potential benefit of this research is that it could help future patients with lung cancer by improving our understanding of how immunotherapy works, leading to better treatment choices and possibly fewer side effects. As no active participation is required, the right to withdraw active involvement doesn't apply in the usual sense, as the data and samples are already collected and anonymised.

Locations (1)

CHRU de Brest
Verified postcode
Brest, France· Recruiting

Common questions

What is advanced non-small cell lung cancer?

This is a common type of lung cancer that has spread beyond the lung where it started or is too large to be fully removed by surgery.

What is pembrolizumab?

It's an immunotherapy drug, often known by the brand name Keytruda, that helps your body's immune system fight cancer cells.

What does 'retrospective' mean for a study?

It means the study looks back at information from patients who have already received treatment in the past, rather than involving new patients and new treatments.

Will this study change my current treatment?

No, this study is about past treatments and will not affect any current or future treatment you might be receiving.

How will my privacy be protected?

All patient information and samples used in the study are anonymised, meaning your personal identity will not be linked to the research findings.

How to find out more

Margaux GEIER, MD

margaux.geier@chu-brest.fr 02 30 33 80 30 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.